Ligand Pharmaceuticals LGND Long-term portion of financial royalty assets, net
Long-term portion of financial royalty assets, net at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsNonCurrent.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's long-term portion of financial royalty assets, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's long-term portion of financial royalty assets, net?
- Ligand Pharmaceuticals (LGND) reported long-term portion of financial royalty assets, net of $193.54M in Q1 2026.
- How has Ligand Pharmaceuticals's long-term portion of financial royalty assets, net changed year-over-year?
- Ligand Pharmaceuticals's long-term portion of financial royalty assets, net increased by 2.8% year-over-year, from $188.32M to $193.54M.
- What is the long-term trend for Ligand Pharmaceuticals's long-term portion of financial royalty assets, net?
- Over 2 years (2023 to 2025), Ligand Pharmaceuticals's long-term portion of financial royalty assets, net has grown at a 77.8% compound annual growth rate (CAGR), from $62.29M to $196.88M.
- What does long-term portion of financial royalty assets, net mean?
- This represents the long-term portion of financial assets arising from royalty streams that are expected to be collected beyond the next twelve months. It serves as a valuation of the company's long-term intellectual property portfolio and future revenue rights. This metric is critical for evaluating the long-term sustainability of the company's licensing and partnership strategy.